探讨雾化吸入布地奈德治疗小儿哮喘的疗效及免疫功能对比

Investigation on the Efficacy and Immune Function of Aerosolized Budesonide in the Treatment of Children with Asthma

目的对小儿哮喘予以雾化吸入布地奈德治疗,以此对比观察雾化吸入布地奈德治疗后的疗效及免疫功能。方法 2016年9月—2018年9月间选取200例小儿哮喘患者,使用随机数字表法将患者分为:常规治疗(对照组)、雾化吸入布地奈德治疗(研究组)。对组间的治疗总有效率、T细胞亚群CD3+、CD4+、CD8+水平、不良反应发生率进行指标对比。结果研究组的治疗总有效率(98.00%)、T细胞亚群CD3+(63.33±4.44)、CD4+(40.12±3.33)水平均高于对照组[T细胞亚群CD3+、CD4+分别为(57.77±3.66)、(36.67±2.55)],且研究组的T细胞亚群CD8+水平(25.54±1.77)低于对照组(27.11±2.23),差异有统计学意义(χ~2=18.939 4,P=0.000 1;t=9.662 7、P=0.000 1, t=8.225 6、P=0.000 1,t=5.514 4、P=0.000 1);研究组(5.00%)与对照组(6.00%)的不良反应发生率指标差异无统计学意义(χ~2=0.096 2,P=0.756 4)。结论雾化吸入布地奈德治疗小儿哮喘患者可以获得显著的临床治疗效果,并可在一定程度上增加其免疫机能。

Objective To treat children with asthma by aerosolized budesonide,in order to compare the efficacy and immune function of aerosolized budesonide.Methods From September 2016 to September 2018 A total of 200 children with asthma were enrolled.Patients were randomized to receive conventional therapy(control group)and aerosolized budesonide(study group).The total effective rate of treatment,T cell subsets CD3+,CD4+,CD8+levels,and incidence of adverse reactions were compared.Results The total effective rate of treatment(98.00%),T cell subsets CD3+(63.33±4.44),and CD4+(40.12±3.33)were higher in the study group than in the control group[T cell subset CD3+,CD4+were(57.77±3.66),(36.67±2.55)],and the T8 subsets of the study group CD8+level(25.54±1.77)was lower than the control group(27.11±2.23),the difference was statistically significant(χ^2=18.939 4,P=0.000 1;t=9.662 7,P=0.000 1;t=8.225 6,P=0.000 1;t=5.514 4,P=0.000 1);There was no statistical difference in the incidence of adverse reaction between the study group(5.00%)and the control group(6.00%).Academic significance(χ^2=0.096 2,P=0.756 4).Conclusion Inhalation of budesonide in children with asthma can achieve significant clinical treatment and increase the immune function to some extent.